UCB-J

Novel ligand for quantification of synaptic density in brain (SV2A) is produced by PharmaSynth AS

PharmaSynth AS is producing GMP certified BF3-Dm-UCB-J, a precursor for [¹¹C]UCB-J, a selective radioligand for synaptic vesicle glycoprotein 2A (SV2A), as well as its reference standard.

For more information regarding the ligand activity and findings, please consult the publications:

Lower synaptic density is associated with depression severity and network alterations
Holmes, S. E. et.al., Nat Commun. 2019, vol 10, issue 1529.

Imaging synaptic density in the living human brain

Finnema, S. J. et.al., Sci Transl Med. 2016, vol 8, issue 348.

Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein
2A in the Brain

Nabulsi, N. B. et al., J Nucl Med. 2016, 57, 777-784.

Corresponding products in our portfolio:

Reference standard

BF3-Dm-UCB-J

Precursor

For further information regarding technical specifications please contact our chief chemist, Olavi Loog at olavi@pharmasynth.ee or by using the contact form on our webpage.

Novel ligand for quantification of synaptic density in brain (SV2A) is produced by PharmaSynth AS

PharmaSynth AS is producing GMP certified BF3-Dm-UCB-J, a precursor for [11C]UCB-J, a selective radioligand for synaptic vesicle glycoprotein 2A (SV2A), as well as its reference standard.

Corresponding products in our portfolio:

UCB-J

PharmaSynth AS is producing GMP certified BF3-Dm-UCB-J, a precursor for [¹¹C]UCB-J, a selective radioligand for synaptic vesicle glycoprotein 2A (SV2A), as well as its reference standard.